Registration Dossier

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

 No data on carcinogenicity of zinc bis(dibenzyldithiocarbamate) (ZBEC) are available. In accordance with Column 2 of REACH Annex X, a carcinogenicity study may be proposed if the substance is classified as mutagen category 3 or there is evidence from the repeated dose studies that the substance is able to induce hyperplasia and/or pre-neoplastic lesions. Available data on ZBEC indicate that the substance is not genotoxic in vivo. In the 17-week oral study with its structural analogue zinc bis(dibutyldithiocarbamate) (ZDBC) no evidence of pre-neoplastic lesions or hyperplasia was found. Therefore it is concluded that ZBEC is not carcinogenic and the performance of a carcinogenicity study is not indicated.

Key value for chemical safety assessment

Additional information

Justification for classification or non-classification

Based on the lack of genotoxic potential of zinc bis(dibenzyldithiocarbamate) (ZBEC) and the read-across of repeated dose toxicity data with a structural analogue zinc bis(dibutyldithiocarbamate) (ZDBC), classification of ZBEC for carcinogenicity is not warranted in accordance with Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.